Medarex is developing monoclonal antibodies to CTLA-4 and PD-1, which are proteins on the surface of T cells. T cells attack cancer cells, but CTLA-4 and PD-1 act as brakes on the T cell's anti-cancer activities. The monoclonal antibodies bind to those proteins, and release the T cell to attack cancer cells.
In 2009, the U.S. FDA approved Simponi, a human monoclonal antibody for treatment for arthritis, which was co-developed with Johnson & Johnson's Janssen Biotech. In 2011, the U.S. Food and Drug Administration approved Ipilimumab, a monoclonal antibody to CTLA-4, for treatment of metastatic melanoma. The cost is $120,000 for a cost of treatment.
Medarex was founded by Donald Drakeman. The company went public in 1991, with 2,300,000 shares of common stock at $6.10 per share and 2,250,000 Redeemable Warrants offered at its IPO. The company's second president and CEO was Howard H. Pien, succeeding Drakeman in 2007. Genmab was founded as a European spin-off of American Biotech company Medarex in February 1999.
The company was acquired by Bristol Myers Squibb in 2009.
- Breakthrough of the Year: Cancer Immunotherapy, Science 20 December 2013, Vol. 342 no. 6165 pp. 1432-1433, DOI: 10.1126/science.342.6165.1432, Jennifer Couzin-Frankel
- ClinicalTrials.gov NCT00094653
- Marcial, Gene (4 May 2009). "Marcial: Medarex, a Bright Spot in Biotech". businessweek.com. Retrieved 24 Sep 2014.
- "Medarex raises $12.9M in IPO for R&D of Biospecific". 1 May 1991. Retrieved 24 Sep 2014.
- "Life in the Fast Lane: New at Medarex". http://www.pharmamedtechbi.com/. 23 May 2007. Retrieved 24 Sep 2014.
- "Bristol-Myers Squibb to Acquire Medarex". BMS.com. 22 Jul 2009. Retrieved 24 Sep 2014.
- medarex.com Corporate website
|This biotechnology article is a stub. You can help Wikipedia by expanding it.|
|This United States corporation or company article is a stub. You can help Wikipedia by expanding it.|